



An English translation of the Abstract of the non-English PCT publication is included in that document.

This submission does not represent that a search has been made or that no better art exists and does not constitute an admission that each or all of the listed documents are material or constitute "prior art." If the Examiner applies any of the documents as prior art against any claim in the application and Applicants determine that the cited documents do not constitute "prior art" under United States law, Applicants reserve the right to present to the Office the relevant facts and law regarding the appropriate status of such documents.

Applicants further reserve the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application. If there is any fee due in connection with the filing of this Statement, please charge the fee to our Deposit Account No. 06-0916.

Respectfully submitted,

FINNEGAN, HENDERSON, FARABOW,  
GARRETT & DUNNER, L.L.P.

Dated: April 24, 2006

By: 

Kenneth J. Meyers  
Reg. No. 25,146  
Tel.: 202-408-4033  
Fax: 202-408-4400  
Email: ken.meyers@finnegan.com

APR 24 2006

Complete if Known

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

Application Number	10/566,386
Filing Date	January 30, 2006
First Named Inventor	Claude AURIAULT
Art Unit	Not Assigned
Examiner Name	Not Assigned
Attorney Docket Number	03715.0152-00000

## U.S. PATENTS AND PUBLISHED U.S. PATENT APPLICATIONS

Examiner Initials	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Issue or Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-2005-0114910-A1	05-26-2005	Yu-Chin Lone et al.	
		US-2003-101465-A1	05-29-2003	Patricia Lawman et al.	

**Note: Submission of copies of U.S. Patents and published U.S. Patent Applications is not required.**

## FOREIGN PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	Translation <sup>6</sup>
		WO 02/059263 A2	08-01-2003	Sunol Molecular Corp.		
		WO 03/006639 A1	01-23-2003	Genoway		Abstract

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Translation <sup>6</sup>
		ALEXANDER, Jeff, et al., "Derivation of HLA-A11/K <sup>b</sup> Transgenic Mice," <i>Journal of Immunology</i> , vol. 159, No. 10, pp. 4753-4761 (1997).	
		BAKER, Alexander G.H., et al., "Analogus of CTL Epitopes MHC Class-I Binding Capacity Elicit Anti-Melanoma CTL Recognizing the Wild-Type Epitope," <i>Journal of Cancer</i> , vol. 70, pp. 302-09 (1997).	
		BARRA, Claude, et al., "Abrogation of H-2-Restricted CTL Responses and Efficient Recognition of HLA-A3 Molecules in DBA/2 HLA/A24 Responder Mice," <i>Journal of Immunology</i> , vol. 150, No. 9, pp. 3681-89 (1993)	
		BENMOHAMED, Lbachir, et al., "Induction of CTL Response by a Minimal Epitope Vaccine in HLA A*0201/DR1 Transgenic Mice: Dependence on HLA Class II Restricted T <sub>H</sub> Response," <i>Human Immunology</i> , vol. 61, No. 8, pp. 764-79 (2000).	
		CARMON, Lior, et al., "Novel Breast-Tumor-Associated MUC1 Peptides: Characterization in D <sup>b</sup> -/- x $\beta$ Microglobulin ( $\beta$ 2m) Null Mice Transgenic for a Chimeric HLA-A2.1/D <sup>b</sup> - $\beta$ 2 Microglobulin Single Chain," <i>International Journal of Cancer</i> , vol. 85, pp. 391-97 (2000).	
		ELLIOTT, Suzanne L., et al., "Peptide based cytotoxic T-cell vaccines; delivery of multiple epitopes, help, memory and problems," <i>Vaccine</i> , vol. 17, pp. 2009-2019 (1999).	
		EPSTEIN, Helen, et al., "Expression and Function of HLA-A2.1 in Transgenic Mice," <i>European Journal of Immunology</i> , vol. 7, pp. 1575-83 (1989).	
		HILL, Adrian V.A., The Immunogenetics of Human Infectious Diseases, <i>Annual Review of Immunology</i> , vol. 16, pp. 593-616 (1998).	
		LE, Ai-Xuan T., "Cytotoxic T Cell Responses in HLA-A2.1 Transgenic Mice," <i>J. of Immunology</i> , vol. 142, No. 4, pp. 1366-1371 (1989).	
		LUSTGARTEN, Joseph et al., "Identification of Her-2/Neu CTL Epitopes Using Double Transgenic Mice Expressing HLA-A-2.1 and Human CD.8," <i>Human Immunology</i> , vol. 52, No. 2, pp. 109-118 (1997).	
		MADSON, Lars et al., "Mice lacking all conventional MHC class II genes," <i>Proceedings of the National Academy of Sciences</i> , vol. 96, pp. 10338-43 (1999).	
		NISHIMURA, Yasuharu et al., "Expression of the Human MHC, HLA-DQW6 Genes Alters the Immune Response in C57BL/6 Mice," <i>Journal of Immunology</i> , vol. 145, No. 1, pp. 353-60 (1990)	
		PAJOT, Anthony et al., "A mouse model of human adaptive immune functions: HLA-A2.1-/HLA-DR1-transgenic H-2 class I-/class II-knockout mice," <i>European Journal of Immunology</i> , vol. 34, No. 11, pp. 3060-69 (2004).	
		PAJOT, Anthony et al., "Comparison of HLA-DRI transgenic mice deficient for murine MHC class II and HLA-DRI transgenic mice expressing endogenous murine MHC class II molecules," <i>International Immunology</i> , vol. 16, No. 9, pp. 1275-82 (2004).	

APR 24 2006

## Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

2

of

2

Application Number

10/566,386

Filing Date

January 30, 2006

First Named Inventor

Claude AURIAULT

Art Unit

Not Assigned

Examiner Name

Not Assigned

Attorney Docket Number

03715.0152-00000

## NON PATENT LITERATURE DOCUMENTS

PASCOLO, Steve, et al., "HLA-A2.1-restricted Education and Cytolytic Activity of CD8<sup>+</sup> T.Lymphocytes from  $\beta$ 2m HLA-A2.1 Monochain Transgenic H-2D<sup>b</sup>  $\beta$ 2m Double Knockout Mice," *Journal of Experimental Medicine*, vol. 185, No. 12, pp. 2043-51 (1997)

STEINMETZ, Michael et al., "Recent experiments with MHC knock-out mice: More questions than answers," *BioEssays*, vol. 15, No. 9, pp. 613-615 (1993)

VITIELLO, Antonella et al., "Development of a Lipopeptide-based Therapeutic Vaccine to Treat Chronic HBC Infection," *Journal of Clinical Investigation*, vol. 95, pp. 341-49 (1995).

VITIELLO, Antonella, et al., "Analysis of the HLA-restricted Influenza-specific Cytotoxic T Lymphocyte Response in Transgenic Mice Carrying a Chimeric Human-Mouse Class I Major Histocompatibility Complex," *Journal of Experimental Medicine*, vol. 173, No. 4, pp. 1007-15 (1991).

WENTWORTH, Peggy A., et al., "Differences and similarities in the A2-1 restricted cytotoxic T Cell repertoire in humans and human leukocyte antigen-transgenic mice," *European Journal of Immunology*, vol. 29, No. 1 pp. 97-100 (1996)

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.